产品
编 号：F749288
分子式：C17H16N2O3
分子量：296.32
分子式：C17H16N2O3
分子量：296.32
产品类型
规格
价格
是否有货
结构图
CAS No: 2138488-38-5
产品详情
生物活性：
ZT55 is an orally active and highly-selective JAK2 inhibitor with an IC50 value of 0.031 μM. ZT55 inhibits the proliferation of JAK2V617F-expressing HEL cell lines and induces apoptosis and cycle arrest. ZT-55 also effectively inhibits the growth of HEL xenograft tumours in a mice model. ZT-55 can be used in studies of myeloproliferative neoplasms, polycythemia vera and primary thrombocythemia.
体内研究：
ZT55 (100 mg/kg; p.o; once a day for 2 weeks) 显著抑制裸鼠皮下 HEL 肿瘤的生长。Animal Model:Female, athymic BALB/c nude mice (6 to 8-week-old; JAK2V617F xenograft model).
Dosage:100 mg/kg
Administration:Oral administration; once a day for 2 weeks
Result:Induced marked reductions in tumor volume.
体外研究：
ZT55 (0-100 μM; 48 h) 以浓度依赖的方式对 JAK2V617F 表达阳性的 HEL 细胞显示抗增殖活性 (IC50=18.05 μM)。ZT55 (12.5, 25, 50 μM; 24, 48, 72 h) 以浓度和时间依赖的方式抑制 HEL 细胞的活力并诱导细胞凋亡。ZT55 (12.5, 25, 50 μM; 24 h) 以浓度依赖的方式诱导 HEL 细胞阻滞在 G2/M 期。
ZT55 is an orally active and highly-selective JAK2 inhibitor with an IC50 value of 0.031 μM. ZT55 inhibits the proliferation of JAK2V617F-expressing HEL cell lines and induces apoptosis and cycle arrest. ZT-55 also effectively inhibits the growth of HEL xenograft tumours in a mice model. ZT-55 can be used in studies of myeloproliferative neoplasms, polycythemia vera and primary thrombocythemia.
体内研究：
ZT55 (100 mg/kg; p.o; once a day for 2 weeks) 显著抑制裸鼠皮下 HEL 肿瘤的生长。Animal Model:Female, athymic BALB/c nude mice (6 to 8-week-old; JAK2V617F xenograft model).
Dosage:100 mg/kg
Administration:Oral administration; once a day for 2 weeks
Result:Induced marked reductions in tumor volume.
体外研究：
ZT55 (0-100 μM; 48 h) 以浓度依赖的方式对 JAK2V617F 表达阳性的 HEL 细胞显示抗增殖活性 (IC50=18.05 μM)。ZT55 (12.5, 25, 50 μM; 24, 48, 72 h) 以浓度和时间依赖的方式抑制 HEL 细胞的活力并诱导细胞凋亡。ZT55 (12.5, 25, 50 μM; 24 h) 以浓度依赖的方式诱导 HEL 细胞阻滞在 G2/M 期。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备